Astrana Health (3AM) Q2 2026 Earnings Report

The call conveyed strong operational and financial momentum: substantial year-over-year top-line and profitability growth, improved operating leverage from AI-driven automation, meaningful cash generation and accelerated de-leveraging, successful integration of Prospect with expected synergies, and raised EBITDA guidance. Offsetting these positives are ongoing Medicaid membership attrition and program-specific headwinds in California, slightly elevated commercial cost trends, a minor one-time $15 million ACO REACH revenue reduction, and some uncertainty around exchange and Medicaid dynamics. On balance, the positive execution, scale gains, and trajectory of the AI-native operating system materially outweigh the near-term challenges and conservatively guided risks.

Astrana reaffirmed full‑year revenue guidance of $3.8–$4.1 billion, raised full‑year adjusted EBITDA to $255–$280 million, and reaffirmed free cash flow guidance of $105–$132.5 million, while guiding Q3 revenue of $1.00–$1.03 billion and Q3 adjusted EBITDA of $72.5–$77.5 million and expecting G&A to exit the year at roughly 6% of revenue. Management said it will reinvest mid‑ to high‑single‑digit millions of dollars of current outperformance into growth initiatives (new payer/provider contracts and tuck‑ins), continue to capture Prospect synergies at the high end of a $12–$15 million target, and is assuming zero HQAF contribution and conservative Medicaid membership trends. They reported H1 free cash flow of $93 million (≈69% conversion of adjusted EBITDA), retired $92 million of debt in the quarter, ended with $401 million cash and $579 million net debt, and show pro forma net leverage of 2.26x, noting a one‑time $15 million ACO REACH revenue adjustment that was immaterial to EBITDA.